Contents

1. What Happens after a Biopsy or Excision of Breast Tissue? Understanding Specimen Processing and Examination **1**

- Specialty of Pathology *1*
- Specimen Processing *1*
- Specimen Examination *2*

2. Breast Core Biopsies: Diagnosis, Diagnostic Terms and What Do They Mean? **8**

- Benign Lesions that do not Require Surgical Excision *8*
- Benign and Atypical Lesions that may Require Surgical Excision *8*
- Other Uncommon Lesions *11*
- Malignant Lesions *19*

3. Breast Excisions, Lumpectomies and Mastectomies: Reporting on Large Specimens **30**

- Breast Conserving Surgery *30*
- Mastectomy *31*
- Pathology Reports *33*

4. Breast Tumor Morphologic Types **48**

- Adenoid Cystic Carcinoma *48*
- Apocrine Carcinoma *48*
- Cribriform Carcinoma *49*
- Lipid Rich, Histiocytoid, and Glycogen Rich Clear Cell Carcinomas *49*
- Medullary Carcinoma *50*
- Metaplastic Carcinoma *52*
- Micropapillary Carcinoma *52*
- Mucinous Carcinoma *54*
- Neuroendocrine Tumors *56*
- Papillary Carcinoma *56*
- Secretory Carcinoma *58*
- Tubular Carcinoma *58*
- Tubulolobular Carcinoma *59*

5. Diagnostic Immunohistochemistry: How and When Stains Should be Used? **64**

- Assessment of Stromal Invasion *64*
- Immunohistochemistry of Papillary Lesions *66*
- Distinction between Usual Ductal Hyperplasia and Atypical Ductal Hyperplasia *70*
- Ductal Versus Lobular *76*
- Diagnosing Basal-Like Breast Carcinoma Using Immunohistochemistry *76*

- Spindle Cell Lesions of the Breast-Use of Immunohistochemistry *79*
- Paget's Disease of the Breast *80*
- Lymphovascular Space Invasion *85*
- Immunohistochemistry for Sentinel Lymph Nodes *87*
- Use of Immunohistocehmistry In Fibroepithelial Lesions *88*
- Identifying Breast Cancer at Metastatic Site: Crucial Role Played by Pathologists *89*

6. Current Prognostic/Predictive Marker Testing in Breast Cancer **97**

- Hormone Receptor Testing in Breast Cancer *97*
- Important/Interesting Facts about ER and PR Testing by IHC *98*
- HER2 Testing in Breast Carcinoma *99*
- HER2 IHC *100*
- HER2 FISH *100*
- HER2 Status and Tumor Characteristics *103*
- Does HER2 Status Change at Recurrence or after Therapy? *106*
- Other Relevant Prognostic/Predictive Markers *107*

7. Molecular Testing in Breast Carcinoma **121**

- Intrinsic Gene Set-Based Molecular Classification *121*
- Claudin-Low Tumors *122*
- Molecular Apocrine Tumors *123*
- Clinical/Commercial Multigene Assays *124*
- Pathologist's Perspective on Commercial Multigene Assays *129*
- Future of Molecular Testing in Breast Cancer *130*

8. Neoadjuvant Therapy in Breast Cancer: What Breast Cancer Care Providers Need to Know? **134**

- Predictors of Response *134*
- Assessment of Response *135*
- Therapy-Related Changes *139*

9. Frequently Asked Questions **148**

- Questions and Answers *148*

Index *161*